Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tacrolimus based immunosuppression.

M Roy First1

  • 1Research and Development, Fujisawa Healthcare, Inc., Deerfield, IL 60015-2548, USA. roy_first@fujisawa.com

Journal of Nephrology
|December 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forty-Year Survival of Simultaneous Kidney and Duct-Injected Segmental Pancreas Transplants in a Recipient Maintained on Low-Dose Azathioprine and Prednisone.

Transplantation proceedings·2022
Same author

TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study.

Gastroenterology·2021
Same author

Avoiding surveillance biopsy: Use of a noninvasive biomarker assay in a real-life scenario.

Clinical transplantation·2020
Same author

Kidney Graft Surveillance Biopsy Utilization and Trends: Results From a Survey of High-Volume Transplant Centers.

Transplantation proceedings·2020
Same author

Serial Peripheral Blood Gene Expression Profiling to Assess Immune Quiescence in Kidney Transplant Recipients with Stable Renal Function.

Annals of transplantation·2020
Same author

The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same journal

Lessons for the Clinical Nephrologist. Not to see the forest for the trees: the diagnostic challenge with valproic acid-induced Fanconi-like proximal tubulopathy.

Journal of nephrology·2026
Same journal

Longitudinal trajectories in multidomain frailty among patients with chronic kidney disease.

Journal of nephrology·2026
Same journal

Correction to: Association between primary care physician-nephrologist collaboration and clinical outcomes in patients with stage 5 chronic kidney disease: a JOINT-KD cohort study.

Journal of nephrology·2026
Same journal

Improving eGFR estimation in diabetic populations: insights from real-world data.

Journal of nephrology·2026
Same journal

Barriers delaying treatment in cases at risk of crush syndrome in major disasters: Kahramanmaraş earthquake experience.

Journal of nephrology·2026
Same journal

Ultra-long survivors of kidney transplantation: forty years and more of graft function.

Journal of nephrology·2026
See all related articles

Tacrolimus (Prograf) improves long-term renal transplant survival by reducing rejection and improving kidney function. Recent studies show it has comparable rates of post-transplant diabetes mellitus (PTDM) to cyclosporine.

Area of Science:

  • Nephrology
  • Immunosuppression
  • Transplantation

Background:

  • Long-term success in renal transplantation depends on managing rejection, renal dysfunction, and cardiovascular risks.
  • Tacrolimus (Prograf) is a key immunosuppressant in transplantation.
  • Cardiovascular risk factors include hypertension, hyperlipidaemia, and post-transplant diabetes mellitus (PTDM).

Purpose of the Study:

  • To evaluate the impact of tacrolimus-based immunosuppression on long-term renal transplant outcomes.
  • To compare tacrolimus with cyclosporine regarding efficacy and safety, focusing on rejection, renal function, and cardiovascular risk factors.

Main Methods:

  • Review of clinical trials and registry studies over the past decade.
  • Comparison of tacrolimus and cyclosporine treatment groups.

Related Experiment Videos

  • Analysis of outcomes including acute/chronic rejection, renal function, hypertension, hyperlipidaemia, and PTDM incidence.

    • Main Results:

    • Tacrolimus is associated with decreased acute and chronic rejection compared to cyclosporine.
    • Tacrolimus improves long-term renal function post-transplantation.
    • While early studies showed higher PTDM rates with tacrolimus, recent trials indicate no significant difference compared to cyclosporine microemulsion.

    Conclusions:

    • Tacrolimus-based immunosuppression may lead to improved long-term renal transplant outcomes.
    • Tacrolimus offers benefits in reducing rejection and improving renal function.
    • The incidence of PTDM is comparable between tacrolimus and cyclosporine microemulsion, addressing earlier concerns.